Physician profile
Lora Smith
NPI 1225323090
$1,240.94
in general payments reported to CMS, 2019-2025
18 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $235 · 2022: $594 · 2023: $154 · 2024: $104 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $412.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $448.17 | 2021-2025 | |
| Novo Nordisk INC | $206.79 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $136.18 | 2022-2025 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $82.88 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.97 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.99 | 2021-2022 | |
| Boston Scientific Corporation | $45.33 | 2024-2025 | Watchman Flx, Watchman Access System |
| Glaxosmithkline, LLC. | $32.00 | 2022 | |
| Lilly USA, LLC | $31.72 | 2021-2022 | |
| Pfizer INC. | $18.69 | 2024 | |
| Axsome Therapeutics, INC. | $17.81 | 2024 | Auvelity |
| Exeltis, USA INC. | $17.04 | 2023 | Slynd |
| Antares Pharma, INC. | $15.79 | 2025 | Xyosted |
| Genentech USA, INC. | $14.98 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $14.86 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $13.24 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.01 | 2022 | |
| Phathom Pharmaceuticals, INC. | $9.49 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lora Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.